JP2017507943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507943A5 JP2017507943A5 JP2016553897A JP2016553897A JP2017507943A5 JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5 JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- neu
- osteosarcoma
- listeria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 | 2014-02-25 | ||
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 | 2014-05-02 | ||
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| US62/076,411 | 2014-11-06 | ||
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507943A JP2017507943A (ja) | 2017-03-23 |
| JP2017507943A5 true JP2017507943A5 (enExample) | 2018-08-02 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553897A Pending JP2017507943A (ja) | 2014-02-25 | 2015-02-25 | Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3110942A4 (enExample) |
| JP (1) | JP2017507943A (enExample) |
| KR (2) | KR20160122829A (enExample) |
| CN (1) | CN106661538A (enExample) |
| AU (1) | AU2015223136A1 (enExample) |
| BR (1) | BR112016019534A2 (enExample) |
| CA (1) | CA2940646A1 (enExample) |
| IL (1) | IL247436A0 (enExample) |
| MX (1) | MX2016011114A (enExample) |
| RU (1) | RU2016137834A (enExample) |
| SG (1) | SG11201607036XA (enExample) |
| WO (1) | WO2015130810A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
| EP3107566A4 (en) | 2014-02-18 | 2017-10-11 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| MA39717A (fr) * | 2014-03-05 | 2017-01-11 | Advaxis Inc | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs |
| SG11201608820WA (en) | 2014-04-24 | 2016-11-29 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| CN110506107A (zh) | 2016-11-30 | 2019-11-26 | 阿德瓦希斯公司 | 靶向复发性癌症突变的免疫原性组合物及其使用方法 |
| US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
| ES3029080T3 (en) | 2017-10-10 | 2025-06-23 | Seattle Project Corp | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en not_active Ceased
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507943A5 (enExample) | ||
| JP2013526837A5 (enExample) | ||
| RU2016137834A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu | |
| US9969986B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| JP6538622B2 (ja) | ホモ二量体タンパク質コンストラクト | |
| KR102713707B1 (ko) | 신규 다가 나노입자 기반 백신 | |
| JP2017195888A5 (enExample) | ||
| ES2675825T3 (es) | Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2 | |
| JP2017513502A5 (enExample) | ||
| JP2018508212A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| US20160200775A1 (en) | Virus like particle comprising modified envelope protein e3 | |
| JP6786074B2 (ja) | エキソソーム標的ｄｎａワクチン | |
| KR20170092626A (ko) | 재조합 리스테리아 균주의 병용 요법 | |
| AU2017211387A1 (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
| JP6406647B2 (ja) | 細胞性免疫誘導ワクチン | |
| Fioretti et al. | Recent advances in design of immunogenic and effective naked DNA vaccines against cancer | |
| CN115397462A (zh) | 个体化治疗性抗癌疫苗 | |
| JPWO2020097393A5 (enExample) | ||
| KR20240024800A (ko) | 암호화된 아주반트를 포함하는 백신 조성물 | |
| US11844824B2 (en) | Nucleic acid molecules and methods of using the same | |
| JP2024054375A (ja) | エキソソーム標的ｄｎａワクチン | |
| NZ723750B2 (en) | Compositions and methods for the treatment of her2/neu over-expressing tumors | |
| Bequet-Romero et al. | Mutated variant of human vascular endothelial growth factor as a vaccine candidate for cancer immunotherapy |